Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
SJ Valk, C Kimber, E Dorando, I Monsef… - Cochrane Database …, 2021 - cochranelibrary.com
Cochrane Database of Systematic Reviews, 2021•cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are being investigated as potential therapies
for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of
evidence regarding benefits and risks of these interventions is required. Objectives Using a
living systematic review approach, to assess whether convalescent plasma or hyperimmune
immunoglobulin transfusion is effective and safe in the treatment of people with COVID‐19; …
in patients with viral respiratory diseases, and are being investigated as potential therapies
for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of
evidence regarding benefits and risks of these interventions is required. Objectives Using a
living systematic review approach, to assess whether convalescent plasma or hyperimmune
immunoglobulin transfusion is effective and safe in the treatment of people with COVID‐19; …
Background
Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required.
Objectives
Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID‐19; and to maintain the currency of the evidence.
cochranelibrary.com